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Contribution of New Adenomatous 
polyposis predisposition Genes 
in an Unexplained Attenuated 
spanish Cohort by Multigene panel 
testing
Víctor Lorca1, Daniel Rueda2, Lorena Martín-Morales1, María Jesús Fernández-Aceñero3, 
Judith Grolleman4, Carmen poves5, patricia Llovet  1, sandra tapial2, Vanesa García-
Barberán1, Julián sanz3, pedro pérez-segura  6, Richarda M. de Voer4, eduardo Díaz-Rubio6, 
Miguel de la Hoya1, trinidad Caldés1 & pilar Garre  1
Attenuated adenomatous polyposis (AAp) is a heterogeneous syndrome in terms of clinical 
manifestations, heritability and etiology of the disease. Genetic heterogeneity and low penetrance 
alleles are probably the best explanation for this variability. Certainly, it is known that APC and MUTYH 
are high penetrance predisposition genes for adenomatous polyposis, but they only account for 5–10% 
of AAp. other new predisposition genes, such as POLE, POLD1, NTHL1, AXIN2 or MSH3, have been 
recently described and have been associated with AAp, but their relative contribution is still not well 
defined. In order to evaluate the genetic predisposition to AAP in a hospital based population, germline 
DNAs from 158 AAP subjects were screened for genetic variants in the coding regions and intron-exon 
boundaries of seven associated genes through a next-generation sequencing (NGs) custom gene panel. 
splicing, segregation studies, somatic mutational screening and RNA quantitative expression assays 
were conducted for selected variants. In four of the probands the adenoma susceptibility could be 
explained by actionable mutations in APC or MUTYH, and one other patient was a double carrier of two 
truncating variants in both POLE and NTHL1. Furthermore, 16 additional patients harbored uncertain 
significance variants in the remaining tested genes. This report gives information about the contribution 
of the newly described adenomatous polyposis predisposition genes in a spanish attenuated polyposis 
cohort. our results highly support the convenience of NGs multigene panels for attenuated polyposis 
genetic screening and reveals POLE frameshift variants as a plausible susceptibility mechanism for AAp.
Attenuated adenomatous polyposis (AAP) is usually defined by the presence of more than 10 and less than 100 
adenomas along the large intestine and/or rectum. It is a highly heterogeneous syndrome in terms of polyposis 
severity, family history, and lifetime risk of colorectal cancer (CRC)1–3. Adenoma burden can be low or mild, it 
may be accompanied by hyperplastic or serrated polyps, the polyposis diagnosis age is variable and later than clas-
sical forms, and CRC risk can range from 40% to 80% depending on the adenoma burden. A positive family his-
tory is frequently absent, but horizontal or vertical inheritance patterns are also observed. The diffusion of early 
detection CRC screening programs, together with the improvement of colonoscopy techniques, has given rise to 
an increase in the detection of patients with multiple colorectal adenomas. These patients are referred to the onco-
genetic counseling units for genetic testing in order to find an explanation to their adenoma susceptibility that 
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helps in the understanding of the disease and makes possible a satisfactory genetic counseling. Nowadays, APC 
(MIM *611731) and MUTYH (MIM *604933) are the two main clinical actionable predisposition genes for ade-
nomatous polyposis3. That means prevalence and cancer risk estimations are well-defined, allowing an accurate 
genetic counseling and effective high risk monitoring programs for carriers. They both together explain the vast 
majority of classical adenomatous polyposis (>100 adenomas), but they are only able to explain a small fraction 
of AAP2. In fact, in our hospital settings, we are not able to explain more than 5–10% of the patients referred to 
our laboratory after the routine genetic tests. Therefore, the identification of the underlying susceptibility causes 
of those unexplained AAP cases is a priority in our laboratory.
Recently, other adenomatous polyposis predisposition genes, such as POLE4, POLD14, NTHL15, MSH36 and 
AXIN27 (MIM *174762, *174761, *602656, *600887 and *604025, respectively), have been described. However, 
they are still not well characterized and only a few reports have attempted to estimate the extent to which some 
of these genes, individually, are involved in different CRC populations8–13. Therefore, they are still poorly imple-
mented in the daily clinical practice.
Under this scenario of high genetic heterogeneity, the use of next-generation sequencing (NGS) gene pan-
els for the diagnosis of hereditary AAP seems to be the best choice. Aiming to delve into the genetic study of 
unexplained AAP, we have screened the whole coding sequences and intron-exon boundaries of APC, MUTYH, 
POLE, POLD1, NTHL1, MSH3 and AXIN2 in a cohort of AAP collected at our oncogenetic counseling unit. The 
main objective of this work is to determine the contribution of the AAP associated genes in an unexplained AAP 
cohort.
Results
Clinical features of the study cohort. A clinical description of the study cohort is summarized in Table 1. 
The study cohort consisted of 158 AAP patients, coming from the Oncogenetic Counseling Units of Hospital 
Clínico San Carlos and Hospital 12 de Octubre, in Madrid. The average polyposis diagnosis age was 62.9 (ranged 
from 33 to 80) and the average polyp burden 31.2 (from 10 to 100). Detailed clinical description of participants 
is given in Suppl. Table 1.
Germline DNA screening. After genetic panel screening, the average read depth per sample was 895 
reads, with a minimum count of 326 and a maximum of 4616. However, two regions showed reiterative low 
coverage, so they were reanalyzed by high resolution melt (HRM) analysis, NM_000038.4: exon 13 (APC) and 
NM_00128425.1: exon 15 (MUTYH). Once the screening was completed, 28 variants located in six genes were 
validated in 24 patients (Table 2).
Eight patients harbored pathogenic variants (class-5): Two patients harbored class-5 variants in APC, one 
patient was a biallelic carrier of two class-5 variants, another was MUTYH biallelic carrier of a class-5 and a 
class-3 variants, and three patients were monoallelic MUTYH class-5 carriers. Finally, one patient was a dou-
ble carrier of two deleterious variants, in POLE and NTHL1. The remaining sixteen patients harbored class-3 
(Table 2).
Reclassification of variants. After the splicing, segregation and somatic analyses, it was possible to confirm 
two MUTYH variants (c.739C > G; p.(Arg247Gly) and c.1510_1517delinsCCAACAGCCA; p.Thr504Profs*68) 
as likely pathogenic (class-4) and pathogenic (class-5), respectively, and to reclassify the variant POLD1: 
c.2007-5C > T as benign (class-1) and POLE: c.6716C > T p.(Ala2239Val) as likely benign (class-2) (Table 2, 
Suppl. Table 3A,B). In the end, 11 out of 28 variants were classified as class-5 or -4, two variants were classified 
as class-1 or -2, discarding their involvement in the AAP predisposition, and 15 variants remained as uncertain 
significance (class-3) variants.
MUTYH:c.739C > G p.(Arg247Gly). MUTYH variant c.739C > G; p.(Arg247Gly) was detected in trans (Suppl. 
Fig. 1a) with c.1187G > A; p.(Gly396Asp) in a male with more than 20 adenomas at the age of 37. One of his broth-
ers was also a carrier of both variants and presented more than 50 adenomas and CRC at the age of 41(Fig. 1a). 
The variant is located in the hMSH6 binding domain, and missense mutations located in this domain have been 
shown to affect the A/8-oxoG binding and glycosylase activities14. Adenomatous tissue from the proband was 
screened for somatic mutations and G > T changes were found in APC, KRAS, TP53 and MAP2K (Table 3, ID 
AAP COHORT
N 158
% males (n) 73.4 (116)
Dx Age; average (range) 62.9 (33–80)
N adenoma; average (range) 31.2 (10–100)
% hyperplastic polyp detection (n) 44.3 (70)
% dominant inheritance pattern (n) 22.2 (35)
% recessive inheritance pattern (n) 30.4 (48)
% isolated case (n) 47.5 (75)
% full-blown AAP† (n) 83.5 (132)
Table 1. Clinicopathological characteristics of the study cohort. †Full-blown AAP = subjects with more than 20 
adenomas or 10 synchronous adenomas.
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35). As it is well known, adenomas and tumors coming from MUTYH biallelic carriers show a deficiency in the 
8-oxo-hidroxyguanine repair system, leading to an increase in the G > T mutation rate, frequently in APC and 
KRAS15. Thus, c.739C > G; p.(Arg247Gly) was reclassified as class-4 (Suppl. Table 3).
MUTYH:c.1510_1517delinsCCAACAGCCA p.Thr504Profs*68. MUTYH variant c.1510_1517delinsCCAA-
CAGCCA p.(Thr504Profs) was detected in trans (Suppl. Fig. 1b) with c.1187G > A; p.(Gly396Asp) in a male 
with more than 40 adenomas at the age of 56. In this instance, the subject did not present a family history of 
polyposis or CRC (Fig. 1a). Blood derived cDNA sequencing revealed an extension corresponding to 22 amino 
acids after the stop codon (p.Thr504Profs*68). The novel frameshift variation was located at the 3′-end of the 
coding sequence, altering the amino acid sequence of the whole proliferating cell nuclear antigen (PCNA) bind-
ing domain, which is essential for MUTYH’s activity during DNA replication16. Indeed, point mutations at the 
PCNA-binding domain have been proven to decrease the activity of the enzyme17. Somatic analysis of DNA from 
affected adenomas showed G > T changes at KRAS locus (Table 3, ID 89). Therefore, c.1510_1517delinsCCAA-
CAGCCA p.Thr504Profs*68 was reclassified as class-5 (Suppl. Table 3).
POLD1:c.2007-5C > T. After cDNA analysis, no splicing alteration was detected in the c.2007-5 carrier. So it 
was reclassified as class-1.
POLE:c.6716C > T p.(Ala2239Val). POLE variant c.6716C > T p.(Ala2239Val) was detected in homozygosis in 
both an affected and a healthy member, and it was absent in another affected member. Therefore, it was reclassi-
fied as class-2 variants.
Co-occurrence of truncating variants at POLE and NTHL1 loci. Two heterozygous truncating var-
iants, POLE:c.141delG; p.Phe48Leufs*6 and NTHL1:c.268C > T; p.Gln90*, were detected in the same germline 
DNA (Fig. 2a). The patient was a woman with full-blown late AAP diagnosed at the age of 70 and without a 
GENE ID CHANGE (HGVS) rs ID gnomAD† PD‡ CL§
APC
3 c.266C > G p.(Ser89*) nd NA 5
9 c.147_150del p.(Lys49Asnfs*20) nd NA 5
34 c.1966C > G p.(Leu656Val) rs577466163 0 ARM 3
133 c.7399C > A p.(Pro2467Thr) rs372305287 1e-04 APC basic 3
136 c.8501A >C p.(His2834Pro) nd EB1_hDLG 3
139 c.1240C > G p.(Arg414Cys) rs137854567 nd — 3
AXIN2
55 c.2141G > A p.(Arg714Gln) rs762872515 0 — 3
79 c.203G > A p.(Arg68Gln) rs138056036 2e-04 AXIN1_TNKS 3
MUTYH
35 c.1187G > A p.(Gly396Asp) rs36053993 4.8e-03 NUDIX 4 5
35 c.739C > G p.(Arg247Gly) nd ENDO3c 4
37 c.1187G > A p.(Gly396Asp) rs36053993 4.8e-03 NUDIX 4 5
38 c.1187G > A p.(Gly396Asp) rs36053993 4.8e-03 NUDIX 4 5
61 c.667A > G p.(Ile223Val) rs200872702 3.4e-04 ENDO3c 3
89 c.1187G > A p.(Gly396Asp) rs36053993 4.8e-03 NUDIX 4 5
89 c.1510_1517delinsCCAACAGCCA p.Thr504Profs*68 nd NA 5
99 c.1187G > A p.(Gly396Asp) rs36053993 4.8e-03 NUDIX 4 5
NTHL1
16 c.527T > C p.(Ile176Thr) rs1805378 2.2e-03 ENDO3c 3
75 c.856G > A p.(Gly286Ser) rs139309757 3.2e-05 ENDO3c 3
82 c.527T > C p.(Ile176Thr) rs1805378 2.2e-03 ENDO3c 3
83 c.268C > T p.(Gln90*) rs150766139 2.0e-03 NA 5
POLD1
116 c.2007-5C > T rs199506387 2.5e-04 NA 1
118 c.520C > T p.(Arg174Trp) rs749334182 2.7e-05 POLBc-exo 3
152 c.2052G > C p.(Gln684His) rs144143245 6.3e-04 POLBc-pol 3
157 c.1465G > A p.(Val489Met) rs753244422 3.3e-05 POLBc-exo 3
POLE
16 c.3857G > A p.(Arg1286His) rs771823596 5e-05 low complex 3
21 c.6716C > T p.(Ala2239Val) rs190813054 8e-06 — 2
83 c.141delG p.(Phe48Leufs*6) rs761329565 0 NA 4
147 c.198G > A p.(Met66Ile) rs764962999 0 — 3
Table 2. Validated variants and classification according to ACMG-SHERLOC criteria42. All variants were 
heterozygous. †GnomAD (08/06/2018): European (Non-Finish) population frequencies (Exome + Genome). 
‡PD = Protein domain from SMART protein database: NA = not applicable. §CL: variant classification: 
1 = benign; 2 = likely benign; 3 = uncertain significance; 4 = likely pathogenic; 5 = pathogenic. Reference 
sequences: APC: NM_000038, NP_000029; AXIN2: NM_004655, NP_004646; MUTYH: NM_001128425, 
NP_036354; NTHL1: NM_002528, NP_002519; POLD1: NM_001256849, NP_001121897; POLE: NM_006231, 
NP_006222.
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previous family history of polyposis or CRC. Segregation analyses could only be achieved in two of her daughters, 
detecting POLE:c.141delG; p.Phe48Leufs*6 in one of them, who had been diagnosed of a low grade dysplastic 
tubular adenoma at the age of 46 (Fig. 2b).
In order to investigate the involvement of these variants in the adenoma and CRC formation, four adenomas 
(83AD1, 83AD3, 83AD4, 83AD5) and one adenocarcinoma (Haggit-0) (83AC1) from the proband were analyzed 
for somatic mutations (Table 3, ID 83). A total of 13 driver mutations was detected, two of which were indels, four 
C > A changes and seven were C > T changes. Eleven somatic mutations were located in genes involved in the 
early adenoma formation (APC, RNF43 and CTNNB1), whereas two mutations were detected in genes involved 
in later stages (ARID1A, NRAS).
In addition, NTHL1 and POLE specific wild type allele expression was checked at tissue level. Quantification 
analyses were performed in three adenomas (83AD1, 83AD3, 83AD4), one adenocarcinoma (83AC1) and 
healthy colon tissue from the proband (83COLON). POLE wild type allele expression in the carrier’s colon 
tissue (83COLON) did not show a significant change compared to the colon control pool (fold difference 
(FD) = 0.94 ± 0.27, ρ = 0.82), whereas NTHL1 wild type allele expression in 83COLON did (FD = 0.30 ± 0.08, 
ρ = 0.004).
Both POLE and NTHL1 transcripts were over-expressed in the CRC control pool (FDPOLE = 2.06 + 0.08, 
ρ = 0.003; FDNTHL1 = 1.87 + 0.28, ρ = 0.018). However, all adenomas and the adenocarcinoma tested from the car-
rier showed a decrease in the expression of POLE wild type allele (FD average = 0.46 ± 0.20, ρ < 0.001), whereas 
NTHL1 wild type allele showed significant over-expression in one adenoma and one adenocarcinoma from the 
proband when compared to its healthy tissue (ρ = 0.0156 and ρ < 0.001, respectively) (Fig. 2c,d).
Discussion
AAP is becoming one of the largest groups of patients attending our Genetic Counselling Unit. Genetic screen-
ing of MUTYH and APC is recommended in those cases with more than 10 adenomas18. The diagnostic 
approach in our hospital consists in the screening of the four most prevalent MUTYH mutations in Spanish 
population19, c.536A > G; p.(Tyr179Cys), c.1187G > A; p.(Gly396Asp), c.1227_1228dup; p.(Glu410Glyfs*43) and 
c.1437_1439delGGA; p.(Glu480del), and the subsequent screening of point mutations and copy number varia-
tions (CNVs) in the whole coding sequence of the APC gene in those cases with a higher polyp burden and high 
suspicion of inheritance pattern. However, by this approach we are only able to explain around 5% of the cases 
with more than 10 adenomas, or 7% when restricting the criteria to full-blown polyposis (more than 20 adenomas 
or 10 synchronous adenomas). In order to improve the diagnostic sensitivity and investigate the contribution of 
currently known high-penetrance adenomatous polyposis genes in our AAP population, we have conducted a 
Figure 1. Pedigrees of the explained polyposis cases. (a) MUTYH biallelic mutations carrier families. (b) APC 
mutations carrier families. †polyposis diagnosis after family mutation identification. Black square = cancer; 
black circle = >10 adenomas; +=variant carrier; −non carrier; +/+biallelic carrier; GC = gastric cancer; 
CRC = colorectal cancer; BC = breast cancer; y = years; A = adenomas.
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genetic screening in an unexplained AAP cohort through a custom gene panel, including APC, MUTYH, POLE, 
POLD1, NTHL1, AXIN2 and MSH3 coding regions.
Our study cohort was made up of 158 subjects, 132 (83.5%) of which fulfilled the clinical criteria for full-blown 
polyposis (Table 1). There is only a very recent cross-sectional study analyzing the prevalence of pathogenic var-
iants in genes associated with colorectal polyposis and/or CRC in a cohort of 3789 polyposis patients, of which 
2979 presented between 10 and 100 adenomas. All patients underwent panel testing of at least 14 CRC predisposi-
tion genes, including APC and MUTYH. However, only POLD1 and POLE were tested on a subset of the adenoma 
cohort, and the remaining adenomatous polyposis predisposition genes (NTHL1, AXIN2 and MSH3) were not 
tested20. Therefore, this is the largest multiple polyposis cohort in which joint genetic screening for the full coding 
sequences of all AAP predisposition genes has been done so far.
Two APC truncating mutations were detected in two subjects diagnosed with late-onset full-blown polyposis 
and a family history initially suspicious of recessive inheritance (Fig. 1b). Both had been previously tested for 
MUTYH but not for APC, probably due to the lack of family information at the time of diagnosis, the late poly-
posis onset of the probands, and also the stricter clinical criteria for the recommendation of full APC mutational 
screening for AAP in our hospital.
In addition, the screening of the whole coding sequence of MUTYH, allowed the detection of two MUTYH 
non-recurrent mutations, c.739C > G p.(Arg247Gly) and c.1510_1517delinsCCAACAGCCA p.Thr504Profs*68, 
IDP† IDS‡ HIST§ GENE CHANGE TRIPLET CHANGE (HGVS)
% 
ALT¶ MET††
83
AD5 LDTA
APC C > C/T GCG > GTG c.4348C > T p.(Arg1450*) 5.7 TST
APC C > C/A TCA > TAA c.4381G > T p.(Glu1461*) 6.6 TST
CTNNB1 C > C/T TCT > TTT c.134C > T p.(Ser45Phe) 12.9 TST
AD4 LDTA
ARID1A C > C/T ACA > ATA c.514C > T p.(Gln172*) 26 MIP
APC C > C/T GCG > GTG c.2626C > T p.(Arg876*) 8 MIP/TST
APC AAG > AAG/A c.3924_3925delAG p.(Glu1309Lysfs*5) 8.8 MIP/TST
APC GA > GA/G c.3926delA p.(Lys1310Argfs*11) 21 MIP/TST
AC1 ACH0
APC C > C/A TCT > TAT c.3916G > T p.(Glu1306*) 32 MIP/TST
RNF43 C > C/T CCA > CTA c.745C > T p.(Gln249*) 12 MIP
NRAS C > C/T ACC > ATC c.38G > A p.(Gly13Asp) 4.5 TST
AD1 LDTA
APC C > C/T GCG > GTG c.1660C > T p.(Arg554*) 15 MIP
APC C > C/A TCA > TAA c.4189G > T p.(Glu1397*) 13 MIP
AD3 LDTA APC C > C/A TCT > TAT c.3916G > T p.(Glu1306*) 34.8 TST
35
AD1
LDTA APC CC > CC/TA c.4479_4480delGGinsAT p.(Glu1494*) 18.3 TST
LDTA MAP2K1 C > C/A GCT > GAT c.171G > T p.(Lys57Asn) 16.8 TST
LDTA TP53 C > C/A TCT > TAT c.859G > T p.(Glu287*) 19.1 TST
AD2
LDTA APC C > C/A GCA > GAA c.4230C > A p.(Cys1410*) 7.6 TST
LDTA APC C > C/T GCG > GTG c.2626C > T p.(Arg876*) 6.8 TST
LDTA KRAS C > C/A CCA > CAA c.37G > T p.(Gly13Cys) 6.7 TST
37 AD1
LDTA APC C > C/− c.3955delC p.(Pro1319Leufs*2) 15.7 TST
LDTA TP53 C > C/T GCG > GTG c.524G > A p.(Arg175His) 11.5 TST
38
AD1
TA 
LDTA 
LD
MAP2K1 C > C/A GCT > GAT c.171G > T p.(Lys57Asn) 4.6 TST
AD2 HDTVA APC T > T/− c.4233delT p.(Ser1411Argfs*4) 37.1 TST
61 AD1
LDTA CDH1 −>−/A c.1885_1886insA p.(Leu630Thrfs*33) 7.2 TST
LDTA CTNNB1 T > T/C GTA > GCA c.121A > G p.(Thr41Ala) 12.1 TST
LDTA NRAS C > C/T GCA > GTA c.360G > A p.(Leu120 = ) 50.6 TST
99 AD1
LDTA APC C > C/T GCG > GGG c.4348C > T p.(Arg1450*) 35.7 TST
LDTA FBXW7 C > C/T TCG > TTG c.1436G > A p.(Arg479Gln) 35.5 TST
LDTA KRAS C > C/T CCA > CTA c.34G > A p.(Gly12Ser) 45.6 TST
89
AD1 LDTA KRAS C > C/A CCA > ACA c.34C > A p.(Gly12Cis) >1.5 TH-K
AD2 LDTA KRAS C > C/A CCA > ACA c.34C > A p.(Gly12Cis) >1.5 TH-K
Table 3. Somatic mutations. Somatic mutations detected in adenomas analyzed. †IDP = Pacient ID; 
‡IDS = Sample ID: AD = adenoma AC = adenocarcinoma; §HIST = Histology: LDTA = Low grade dysplastic 
tubular adenoma, ACH0 = Adenocarcinoma arising from adenoma Haggitt 0, HDTVA = High grade dysplastic 
tubulovillous adenoma; ¶% ALT = percentage of altered allele; ††MET = Method: TST = TruSight Tumor 26 
panel (Illumina); MIP = single molecule Molecular Inversion Probe; TH-K = Therascreen®KRAS. Reference 
sequences: APC: NM_000038, NP_000029; CTNNB1: NM_001098210, NP_001091680; ARID1A: NM_006015, 
NP_006006; RNF43: NM_017763, NP_060233; NRAS: NM_002524, NP_002515; MAP2K1: NM_002755, 
NP_002746; TP53: NM_000546, NP_000537; KRAS: NM_033360, NP_203524; CDH1: NM_004360, 
NP_004351; FBXW7: NM_033632, NP_361014.
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both in co-occurrence with the recurrent mutation c.1187G > A; p.(Gly396Asp), being able to explain the poly-
posis susceptibility in two more subjects (Fig. 1a).
APC/MUTYH mutational rates are low in AAP population2. Conventional genetic screening technologies 
imply the sequential analysis of each gene amplicon by amplicon, which makes these protocols costly in both time 
and money. Therefore, those laboratories without high sample volumes are forced to restrict their clinical criteria 
for AAP diagnosis in order to make the analysis cost-effective. NGS multigene panels reduce the time and cost 
of these genetic studies, increasing the cost-effectiveness and making the complete screening of samples feasible 
for small laboratories. The identification of pathogenic mutations in APC and MUTYH with an NGS panel in our 
study cohort is a clear example of underdiagnoses, supporting the necessity of parallel sequencing for APC and 
MUTYH routine genetic screening in AAP patients.
None of the patients showed actionable mutations (class-4 and -5) in any of the genes associated with new 
polyposis syndromes (MSH3, NTHL1, POLD1, POLE or AXIN2). However, 10 uncertain significance (class-3) 
variants were detected in AXIN2, NTHL1, POLD1 and POLE (Table 2). Three of these variants were located out-
side the proofreading domain of POLE/POLD1. Although there is no evidence of association between missense 
variants outside these regions and cancer susceptibility, there is a recent report that describes somatic driver 
mutations located outside the exonuclease domains, and suggesting that other domains may be responsible for 
proofreading21. Therefore, we decided to include these variants as class-3 variants for AAP predisposition.
Considering other previous studies that included multiple polyposis cohorts, the frequency of actionable 
mutations in all of these genes seems to be very low in tested populations, but not insignificant (around 1–2%). 
Just like it is not irrelevant the number of variants of uncertain significance that have been described in this and 
other works9,10,12 (1–2% per gene), and whose probable pathogenicity might be proven during the coming years. 
For this reason it is important to include all these genes in the routine analysis of AAP through NGS panels.
A remarkable finding of this work is the detection of a double heterozygous for two truncating variants, at 
exon two of NTHL1 and exon two of POLE (Fig. 2a). The carrier was a woman with late full-blown polyposis, who 
was also diagnosed with endometrial hyperplasia and hypothyroidism (Fig. 2b).
POLE encodes the catalytic subunit of DNA polymerase epsilon, which is responsible for the replication of 
the leading DNA strand during the S phase; it is an essential protein and biallelic truncating mutations are not 
viable. POLE, together with POLD1, is the only nuclear polymerase with an intrinsic 3′–5′exonuclease proofread-
ing activity capable of correcting mistakes made during DNA synthesis22. A few years ago, germline mutations 
Figure 2. Identification of POLE and NTHL1 double heterozygote. (a) POLE and NTHL1 protein domains 
and location of truncating variants detected in patient 83. (b) Pedigree chart; POLE+ = POLE variant carrier; 
POLE− = POLE wild type genotype; NTHL1+ = NTHL1variant carrier; NTHL1− = NTHL1wild type 
genotype; LC = lung cancer; A = adenoma. (c) POLE wild type expression in blood and tissue cDNA samples. 
(d) NTHL1 wild type allele expression in blood and tissue cDNA samples. COLON pool sample has been used 
as a reference sample in both NTHL1 and POLE assays. Significant ρ-values are indicated with *(ρ < 0.05) and 
**(ρ < 0.01). Each sample was analyzed in triplicates. AC = adenocarcinoma; AD = adenoma; CRC = colorectal 
cancer.
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located in the proofreading domain of POLE and POLD1 were associated with adenomatous polyposis predispo-
sition4, showing tumors with a very high mutational burden due to the lack of exonuclease but not polymerase 
activity. According to this, truncating variants at POLE would not be supposed to confer this genetic instability 
because they would lead to a complete inactivation of the enzyme without any polymerase-exonuclease imbal-
ance. However, it is not clear to what extent the lack of one POLE allele can lead to cancer predisposition in some 
other way.
On the other hand, NTHL1 encodes the DNA glycosylase NTHL1, which is involved in removing oxidative 
pyrimidine lesions through the base excision repair (BER) pathway. Resembling to MUTYH-associated polyposis, 
germline biallelic mutations at NTHL1 have been recently associated with adenomatous polyposis predisposi-
tion5, leading to a deficiency in the repair of 5-hydroxycytosine and a consequent increase in the C > T somatic 
mutation rate. Like other glycosylases involved in the BER pathway, NTHL1’s repair activity can be completed by 
a short or long BER patch, mainly depending on the proliferative activity of the cell23. Thus, in high division rate 
tissues NTHL1 is coupled to the DNA synthesis and follows the long-patch BER pathway, dependent of PCNA 
and where POLE and POLD1 are the polymerases responsible for filling the gap after NTHL1’s action and strand 
cleavage23.
Therefore, it is plausible that POLE and NTHL1 co-occurring truncating variants may have a synergistic effect 
leading to a polyposis predisposition in high division tissues such as the colon epithelium. To check this hypoth-
esis, somatic mutation screening and RNA expression analyses were performed in adenomas and CRC from the 
carrier. The analysis of somatic mutations showed a tendency to C > T changes (Table 3), although no clear defi-
nition of the mutational signature could be done due to the low number of mutations. Furthermore, a quantitative 
analysis of POLE wild type allele showed a significant decrease of POLE expression in all tested carrier’s adeno-
mas and adenocarcinoma (Fig. 2c), which is consistent with a replicative stress due to POLE haploinsufficiency. 
However and unlike POLE, NTHL1 expression was increased in two of the carrier’s adenomas and adenocarci-
noma tissues (Fig. 2d). This over-expression was probably triggered by a greater oxidative DNA damage in tissues 
with a high division rate, which has been shown to up-regulate BER glycosylases24. Wild type NTHL1 transcript 
levels in the carrier’s affected tissues reached similar levels than non-carrier’s affected pool, which is not consistent 
with an NTHL1 haploinsufficiency. Therefore, we discarded the involvement of the NTHL1 monoallelic muta-
tion c.268C > T p.(Gln90*) in the polyposis predisposition of this patient and we considered the possibility that 
POLE:c.141delG p.Phe48Leufs*6 could confer the adenoma predisposition by itself. Only 0.005% of POLE coding 
variants described in gnomAD are truncating (frameshift or nonsense); non homozygous have been described 
and all truncating variants show allelic frequencies lower than 1/10000. Moreover, there are two studies in the 
literature describing germline frameshift variants at POLE; c.5621_5622delGT was detected in a sporadic CRC 
patient with a diagnosis age of 2625, and c.1370_1371delAT p.Tyr457fs*9 was later detected in an AAP patient10. 
In addition, as it has been mentioned above, somatic driver mutations have been recently described in POLE and 
POLD1 polymerase domains21.
Furthermore, the presence of both variants was checked in two of the proband’s daughters; one harbored the 
POLE variant, but not the NTHL1 one, and the other did not harbor any of the variants (Fig. 2b). The POLE car-
rier showed a dysplastic tubular adenoma at the age of 46. Despite the large size of the family, no other relatives 
had been diagnosed of cancer or polyposis, which would support the hypothesis of a digenic or oligogenic inher-
itance with other undetected variants or, a de novo POLE mutation in the proband with a dominant effect that is 
not yet possible to observe due to the young age of the daughter harboring the variant (Fig. 2b).
To our knowledge, this is the first report describing the probable association of a truncating germline POLE 
variant with the predisposition of AAP by a haploinsufficiency mechanism in adenomatous and colorectal tumor 
tissues of the carrier. This result highlights not only the genetic heterogeneity and complexity of the syndrome, 
but also the potential of NGS gene panels for the detection and diagnosis of new inheritance forms of complex 
diseases. Further efforts should be done for the study and characterization of germline POLE truncating variants 
in other AAP populations, as well as their co-occurrence with variants in other associated genes.
In accordance with other AAP studies, our results showed a major number of subjects without detection of 
variants in any of the genes tested. It can be thought the involvement of other unknown predisposition genes 
in the susceptibility of AAP and the convenience of wider genetic analysis, such as exome sequencing, for the 
elucidation of new AAP predisposition genes in this unexplained group. However, despite most of the new AAP 
associated genes have been discovered by exome sequencing approaches, there are other works without such suc-
cessful results26,27. The failure of detecting new predisposition genes in AAP is probably due to the high clinical 
and genetic heterogeneity of the condition, as well as the low prevalence of pathogenic mutations in the already 
associated genes. Probably, polygenic inheritance models in which the susceptibility is explained by the accumu-
lation of multiple low penetrance alleles28, and lifestyle risk factors such as smoking, alcohol, body mass index, 
diet and physical activity29 play a major role in the unexplained AAP.
In our cohort, all patients with pathogenic mutation detection presented full blown AAP (more than 20 ade-
nomas) and an average diagnosis age lower than the general study cohort (57.2). Other works analyzing AAP 
cohorts, such as Grover30 who analyzed MUTYH and APC in 4223 patients with 10 to 100 adenomas, or Stanich20 
who also analyze POLD1 and POLE and other CRC genes in 2979 patients with 10 to 100 adenomas, showed 
similar clinical results. These results suggest that the low mutation detection rate in AAP is partially because of 
the lack of strict clinical criteria for the selection of patients with high probability to detect pathogenic mutation 
in any known predisposition gene. Therefore, redefinition of stronger clinical criteria and the use of panel gene 
testing are necessary for the improvement of genetic testing in AAP.
This work is a translational study aiming to analyze the contribution of known and new described adenoma-
tous polyposis predisposition genes and the suitability of their genetic testing in a hospital based cohort that have 
been referred to the genetic counseling unit. The results shown above lead to the following conclusions:
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 1. The contribution of new predisposition genes is much smaller than that of the known genes APC and MU-
TYH. Related pathogenic mutations have not been detected in any gene. However, uncertain significance 
variants have been detected in all genes but MSH3. Since they are recently described genes, the identifica-
tion of potential pathogenic variants and further clarification of their pathogenicity is important for the 
definition of the syndrome.
 2. Somatic genetic screening of affected tissues allows the detection of certain mutational signatures associat-
ed with DNA repair deficiency, helping the classification of the variants.
 3. The expected low mutation detection rate in AAP study cohort point to the necessity of stronger clinical 
criteria for the improvement of the diagnostic sensitivity in AAP genetic testing.
 4. Although the number of POLE/POLD1 truncating mutations detected in AAP cases is very limited, due to 
the genetic heterogeneity of the disease, the relevance of these genes and the decreased levels of carrier’s 
tumor and adenoma samples shown in this work, special attention should be paid to those POLE/POLD1 
truncating variants in order to determine their pathogenicity.
 5. Summarizing, this work highlights the need of multigene panel testing in highly genetic heterogeneous 
syndromes such as AAP, not only to increase the cost-effectiveness and the diagnostic sensitivity of the 
analysis, but also to better detect other potentially pathogenic variants or other inherited forms of the 
disease that would not be detected by other gene directed approaches.
patients and Methods
patients. The inclusion criterion was the detection of between 10 and 100 adenomas in the colon and/or 
rectum. All the samples had been screened, at least, for the most frequent MUTYH (NM_0012222.2) muta-
tions in the Spanish population19: c.536A > G; p.(Tyr179Cys), c.1187G > A; p.(Gly396Asp), c.1227_1228dup; 
p.(Glu410Glyfs*43) and c.1437_1439delGGA; p.(Glu480del), by HRM and/or Sanger sequencing. The presence 
of biallelic MUTYH mutations was considered as an exclusion criterion, but not the presence of monoallelic 
MUTYH mutations. APC screening was not an inclusion criterion, but the previous detection of a pathogenic 
APC mutation was considered as an exclusion criterion.
A total of 158 unrelated AAP cases was included in the study (Suppl. Table 1), comprising 123 subjects from 
Hospital Clínico San Carlos (Madrid) and 35 from Hospital 12 de Octubre (Madrid).
Ethical approval was obtained from Hospital Clínico San Carlos’ Ethical Research Committee (approval num-
ber: C.I.-14/241-E_BS). A written informed consent was obtained from each participant. Methods were compli-
ant with the relevant guidelines and regulations.
sample extraction. Peripheral-blood DNA/RNA extraction was performed with the MagNA Pure 
Compact extractor (Roche), according to the manufacturer’s protocol. Tissue DNA/RNA (from normal epithe-
lium, adenoma or tumor sections) was obtained from formalin-fixed paraffin-embedded (FFPE) tissues with a 
purity greater than 80% as determined by an experienced pathologist. DNA extractions were performed with 
the QIAamp DNA FFPE Tissue kit (Qiagen N.V.) and RNA extractions with the RNAeasy FFPE kit (Qiagen 
N.V.). SuperScript First-Strand Synthesis System for RT-PCR (Thermo Fisher Scientific) was used to synthesize 
cDNA, either from blood or tissue RNA, using random hexamers and oligo-dT, according to the manufacturer’s 
instructions.
Germline DNA screening. Germline DNAs were screened for APC, MUTYH, POLE, POLD1, NTHL1, 
MSH3 and AXIN2 variants in the coding regions and intron-exon boundaries through an NGS Haloplex custom 
panel (Agilent Technologies). Enriched libraries were obtained according to the manufacturer’s protocol, and 
subsequently sequenced on a MiSeq System (Illumina, Inc.). Data analysis and variant calling were achieved 
with the SureCall software (Agilent Technologies) following the recommended pipeline for Haloplex libraries. 
Low covered regions (read depth <50) were analyzed by HRM. CNVs analyses at APC and MUTYH loci were 
performed by multiplex ligation and probe amplification (MLPA) (SALSA® MLPA®probemix P043 and P378, 
MRC-Holland).
All rare (novel or minor allele frequency (MAF) <0.01 according to the gnomAD31 and 1000 genomes pro-
ject32 databases), deleterious or possible deleterious variants (according to protein and/or splicing alteration pre-
diction tools) were selected for validation by Sanger sequencing. MaxEnt, and human splicing finder (HSF)33 were 
used to predict splicing alterations, while SIFT34, Polyphen235 and MutationTaster36 predicted protein damage.
Classification of variants. Variants were classified in five different pathogenicity classes (class-5 or patho-
genic, class-4 of likely pathogenic, class-3 or uncertain significance, class-2 or likely benign and class-1 or benign) 
according to the public mutational databases (InSight37 LOVD38, UMD39, ClinVar40) and supporting pathogenic 
and/or benign evidences, in accordance to the ACMG-SHERLOC criteria41,42.
Characterization of variants. Segregation analyses. Whenever possible, segregation analyses of candidate 
variants were performed on DNA from available family members by Sanger sequencing (oligonucleotides shown 
in Suppl. Table 2).
Splicing analyses. Blood derived cDNAs from patients harboring variants either with a positive splicing altera-
tion prediction or located between five nucleotides from the intron-exon boundaries, were subjected to transcript 
analyses by Sanger sequencing (oligonucleotides shown in Suppl. Table 2).
Adenoma/tumor DNA screening. Adenoma and tumor DNAs were screened for somatic mutations using the 
commercial amplicon-based TruSight Tumor 26 panel (TST26) (Illumina, Inc.), which includes 174 relevant 
9Scientific RepoRts |          (2019) 9:9814  | https://doi.org/10.1038/s41598-019-46403-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
regions located in 26 genes involved in solid tumors. Sequencing was performed on a MiSeq System (Illumina, 
Inc.). Data analysis and variant calling were performed through the plug-in specific Amplicon DS workflow for 
the MiSeq Reporter Software tool (Illumina, Inc.). PASS filter variants, according to the default settings, were first 
selected. Variants that failed to pass default filters, but that were detected in both pools (i.e. showing a low cover-
age depth or strand bias) were manually inspected using the Integrative Genome Viewer (IGV) browser43. Known 
germline polymorphisms, variants detected in the majority of samples tested, variants previously detected in the 
patient’s germline DNA or present in all tested samples from the same subject were discarded.
By single-molecule molecular inversion probe (smMIP) sequencing, two adenomas (83AD1 and 83AD4) and 
one adenocarcinoma (83AC1) were also investigated for the occurrence of somatic mutations in the open reading 
frames and hotspot regions of 57 genes involved in CRC development, as described previously44.
In order to characterize the variant MUTYH:c.1510_1517delinsCCAACAGCCA p.(Thr504Profs*68), three 
adenomas of patient 89 were analyzed for KRAS somatic mutations at codons 12 and 13 by the Therascreen KRAS 
RGQ PCR Kit (Qiagen N.V.), according to the manufacturer’s protocol.
cDNA expression analyses. NTHL1 and POLE wild type allele expression levels were evaluated in three adeno-
mas (83AD1, 83AD3 and 83AD4), one adenocarcinoma (83AC1) and one healthy colon tissue (83COLON) from 
patient 83 and compared to healthy colon and colorectal cancer control pools (COLON and CRC). The healthy 
colon pool was made up of eight FFPE colon tissue-derived RNA samples from unrelated healthy subjects, while 
the colon cancer pool was made up of eight FFPE CRC tissue-derived RNA samples from unrelated patients. All 
samples were previously treated with RNase-free recombinant DNase I (Roche) and the lack of germline DNA 
traces was checked by specific germline and cDNA amplification (Suppl. Fig. 2, primer sequences on Suppl. 
Table 2).
For each of the genes to be tested, primer pairs were designed for the specific detection of the wild type allele, 
and PSMB4 was used as an endogenous gene (Suppl. Table 2). For each sample, 5 ng/μL of RNA was amplified 
in triplicates with the KAPA SYBR® FAST Universal Kit (Roche) in a Light Cycler® 96 (Roche), according to the 
manufacturer’s instructions.
Reclassification of variants. Reclassification of variants was achieved according to the supporting patho-
genic and/or benign evidences, in accordance to the ACMG-SHERLOC criteria41,42
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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